| scholarly article | Q13442814 |
| P2093 | author name string | Andrew D Westwell | |
| Ghali Brahemi | |||
| Alex W White | |||
| P2860 | cites work | Structural basis of caspase-7 inhibition by XIAP | Q24290942 |
| Structural basis for the inhibition of caspase-3 by XIAP | Q24290945 | ||
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis | Q24300734 | ||
| Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain | Q24314763 | ||
| IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases | Q24533214 | ||
| The inhibitors of apoptosis (IAPs) and their emerging role in cancer | Q77900361 | ||
| Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix | Q24537504 | ||
| Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis | Q24609324 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode | Q27732866 | ||
| Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis | Q27734734 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| The atomic structure of protein-protein recognition sites | Q27861113 | ||
| Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 | ||
| Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins | Q28117928 | ||
| Functions of the MDM2 oncoprotein | Q28138115 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Reaching for high-hanging fruit in drug discovery at protein-protein interfaces | Q29547258 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Unraveling hot spots in binding interfaces: progress and challenges | Q29614463 | ||
| Anatomy of hot spots in protein interfaces | Q29616238 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing towards the dream | Q29617758 | ||
| Potential disease targets for drugs that disrupt protein-- protein interactions of Grb2 and Crk family adaptors | Q30159920 | ||
| Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions | Q30886790 | ||
| A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] | Q31106002 | ||
| Exploring protein-protein interactions with phage display | Q31123976 | ||
| Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. | Q31810286 | ||
| Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. | Q33209208 | ||
| Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements | Q33271155 | ||
| Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro | Q33292215 | ||
| Twenty years of p53 research: structural and functional aspects of the p53 protein | Q33807787 | ||
| Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice | Q33982420 | ||
| Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics | Q34059677 | ||
| Mechanism of action of antitumor drugs that interact with microtubules and tubulin | Q34188643 | ||
| Structural insight into microtubule function | Q34301115 | ||
| SH2 domain inhibition: a problem solved? | Q34318063 | ||
| Protein-protein interactions and cancer: small molecules going in for the kill | Q34424260 | ||
| Inhibition of protein-protein association by small molecules: approaches and progress | Q34586778 | ||
| Anticancer therapy with novel tubulin-interacting drugs | Q34657313 | ||
| Apoptosis-based therapies | Q34742803 | ||
| The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions | Q35031256 | ||
| Protein-protein interactions: lessons learned | Q35100538 | ||
| Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3 | Q35101216 | ||
| Decision making by p53: life, death and cancer | Q35116663 | ||
| Antimicrotubular drugs binding to vinca domain of tubulin | Q35584814 | ||
| Targeting Ras and Rho GTPases as opportunities for cancer therapeutics | Q36015529 | ||
| Strategies for targeting protein-protein interactions with synthetic agents. | Q36162137 | ||
| p53 Activation by small molecules: application in oncology | Q36184746 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| Targeting protein-protein interactions for cancer therapy | Q36311496 | ||
| Herceptin: mechanisms of action and resistance | Q36386680 | ||
| How the Bcl-2 family of proteins interact to regulate apoptosis. | Q36394994 | ||
| Drugs targeting protein-protein interactions | Q36558129 | ||
| New approaches to molecular cancer therapeutics | Q36654909 | ||
| Mining the Wnt pathway for cancer therapeutics | Q36670448 | ||
| Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 | ||
| Localization of the colchicine-binding site of tubulin | Q36715788 | ||
| Computational identification of inhibitors of protein-protein interactions. | Q36724095 | ||
| Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases | Q36731111 | ||
| Small molecule inhibitors of the XIAP protein-protein interaction | Q36825005 | ||
| The inhibitors of apoptosis (IAPs) as cancer targets | Q36851057 | ||
| Dangerous habits of a security guard: the two faces of p53 as a drug target | Q36871609 | ||
| An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. | Q40181708 | ||
| Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer | Q40524353 | ||
| Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway | Q40597101 | ||
| Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems | Q40678815 | ||
| Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling | Q40878328 | ||
| Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic | Q40894131 | ||
| Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol | Q41240053 | ||
| Functions of the p53 Protein in Growth Regulation and Tumor Suppression | Q41506167 | ||
| Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? | Q41513765 | ||
| Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. | Q43677077 | ||
| Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor | Q43679854 | ||
| Negatively stained vinblastine aggregates | Q44952123 | ||
| Expression of exogenous wt-p53 does not affect normal hematopoiesis: implications for bone marrow purging. | Q45885615 | ||
| Bcl-2 family proteins | Q46508339 | ||
| Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle | Q47846165 | ||
| Localization of the vinblastine-binding site on beta-tubulin | Q50538479 | ||
| Thymocyte apoptosis induced by p53-dependent and independent pathways | Q54242475 | ||
| Protein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis | Q58044062 | ||
| Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy | Q58282829 | ||
| Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine | Q71119925 | ||
| Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model | Q72198415 | ||
| Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain | Q77158438 | ||
| New insights into microtubule structure and function from the atomic model of tubulin | Q77370497 | ||
| P921 | main subject | protein-protein interaction | Q896177 |
| P304 | page(s) | e8 | |
| P577 | publication date | 2008-03-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Reviews in Molecular Medicine | Q15755244 |
| P1476 | title | Protein-protein interactions as targets for small-molecule therapeutics in cancer | |
| P478 | volume | 10 |
| Q33957616 | ANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery |
| Q34983912 | CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases |
| Q35122366 | Challenges and opportunities in targeting the menin-MLL interaction |
| Q37982406 | Computational Prediction of Protein Hot Spot Residues |
| Q34056558 | Computational alanine scanning with linear scaling semiempirical quantum mechanical methods |
| Q35693426 | DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites |
| Q33552872 | Development and validation of a high-content bimolecular fluorescence complementation assay for small-molecule inhibitors of HIV-1 Nef dimerization |
| Q39006758 | Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. |
| Q24337925 | Distinct binding modes of two epitopes in Gab2 that interact with the SH3C domain of Grb2 |
| Q37831553 | Drug discovery and the human kinome: Recent trends |
| Q42701435 | Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology |
| Q42629379 | Expanding the conformational selection paradigm in protein-ligand docking |
| Q34153589 | From laptop to benchtop to bedside: structure-based drug design on protein targets. |
| Q24339544 | Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions |
| Q33765623 | High-throughput screening for modulators of protein–protein interactions: use of photonic crystal biosensors and complementary technologies |
| Q33786739 | Homology Modelling of Human E1 Ubiquitin Activating Enzyme |
| Q28533728 | Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network |
| Q64092935 | ImmtorLig_DB: repertoire of virtually screened small molecules against immune receptors to bolster host immunity |
| Q33767121 | Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery? |
| Q38563691 | Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions |
| Q35872435 | Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods |
| Q38765380 | Murine ultrasound-guided transabdominal para-aortic injections of self-assembling type I collagen oligomers |
| Q37656544 | On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling |
| Q28475117 | Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing |
| Q41099667 | Osteopontin at the Crossroads of Inflammation and Tumor Progression |
| Q33630135 | PPIMpred: a web server for high-throughput screening of small molecules targeting protein-protein interaction |
| Q44474292 | Prevent protein interactions to prevent cancer metastasis |
| Q99616637 | Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials |
| Q104138421 | Scanning protein surface with DNA-encoded libraries |
| Q35126910 | Self-similarity of human protein interaction networks: a novel strategy of distinguishing proteins |
| Q27671806 | Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia |
| Q34789186 | Systematic prediction of human membrane receptor interactions |
| Q30663340 | TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations |
| Q30398451 | Targeting kinase signaling pathways with constrained peptide scaffolds |
| Q35687836 | Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? |
| Q38157714 | Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy |
| Q37489930 | The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment |
| Q31147980 | The role of HTS in drug discovery at the University of Michigan. |
Search more.